Capital Guardian Trust’s Sarepta Therapeutics SRPT Stock Holding History

Capital Guardian Trust’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-166	Closed	-$3K	–	733
2016 Q2	$3K	Hold	166	–	–	﹤0.01%	639
2016 Q1	$3K	Hold	166	–	–	﹤0.01%	731
2015 Q4	$6K	Hold	166	–	–	﹤0.01%	624
2015 Q3	$5K	Buy	+166	New	+$5.63K	﹤0.01%	645

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital Guardian Trust's SRPT Position: Q3 2016 in Review

Capital Guardian Trust sold out of Sarepta Therapeutics (SRPT) in Q3 2016, closing a stake of 166 shares — an estimated $3K sold.

Capital Guardian Trust first reported a position in SRPT in Q3 2015 and held it in 4 quarters. The position peaked at $6K in Q4 2015. 186 funds tracked by Wall St. Rank hold SRPT as of Q3 2016.

Capital Guardian Trust reported no remaining Sarepta Therapeutics position as of Q3 2016 after selling out during the quarter.
Capital Guardian Trust sold 166 Sarepta Therapeutics shares in Q3 2016, an estimated $3K.
Capital Guardian Trust first reported a position in Sarepta Therapeutics in Q3 2015 and held it in 4 quarters.
Capital Guardian Trust's Sarepta Therapeutics position peaked at $6K in Q4 2015.
186 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2016.

Based on Capital Guardian Trust's 13F filing for Q3 2016, filed 15 Nov 2016.